#checkpointinhibitor — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #checkpointinhibitor, aggregated by home.social.
-
Adcendo inks MSD supply deal to run ADC-Keytruda combination study
Copenhagen-based Adcendo plans to start a Phase Ib trial of the combination in the second half of the…
#Europe #EU #Andtibody-drugconjugates #checkpointinhibitor #combinationtherapy #European #oncology #solidtumour
https://www.europesays.com/europe/53318/ -
Human IL-2 ELISA Kits Market in Romania | Report – IndexBox https://www.byteseu.com/1915723/ #AutoimmuneDiseaseBiomarkerAnalysis #AutomatedLiquidHandlingCompatibility #BiopharmaMarketReport #CancerImmunotherapy(eG #CART #CheckpointInhibitor)Monitoring #Colorimetric/ChemiluminescentDetection #forecast #HumanIL2ELISAKits #ImmunologyAndInflammationResearch #MarketAnalysis #Monoclonal/PolyclonalAntibodyPairs #PreCoatedPlateStabilization #Romania #VaccineImmunogenicityAssessment
-
https://www.europesays.com/be/10130/ Human IL-2 ELISA Kits Market in Belgium | Report – IndexBox #AutoimmuneDiseaseBiomarkerAnalysis #AutomatedLiquidHandlingCompatibility #Belgium #BiopharmaMarketReport #CancerImmunotherapy(eG #CART #CheckpointInhibitor)Monitoring #Colorimetric/ChemiluminescentDetection #forecast #HumanIL2ELISAKits #ImmunologyAndInflammationResearch #MarketAnalysis #Monoclonal/PolyclonalAntibodyPairs #PreCoatedPlateStabilization #VaccineImmunogenicityAssessment
-
Human IL-2 ELISA Kits Market in Belgium | Report – IndexBox https://www.byteseu.com/1914529/ #AutoimmuneDiseaseBiomarkerAnalysis #AutomatedLiquidHandlingCompatibility #Belgium #BiopharmaMarketReport #CancerImmunotherapy(eG #CART #CheckpointInhibitor)Monitoring #Colorimetric/ChemiluminescentDetection #forecast #HumanIL2ELISAKits #ImmunologyAndInflammationResearch #MarketAnalysis #Monoclonal/PolyclonalAntibodyPairs #PreCoatedPlateStabilization #VaccineImmunogenicityAssessment
-
Improving Ovarian Cancer Immunotherapy: Cancer immunologists at the University of Virginia have now discovered what underlies this failure. #immunotherapy #checkpointinhibitor #ovarian #cancer #biome #flagellin
https://www.instagram.com/reel/DHDygk-shuL/ -
Improving Ovarian Cancer Immunotherapy: Cancer immunologists at the University of Virginia have now discovered what underlies this failure. #immunotherapy #checkpointinhibitor #ovarian #cancer #biome #flagellin
https://www.instagram.com/reel/DHDygk-shuL/ -
Improving Ovarian Cancer Immunotherapy: Cancer immunologists at the University of Virginia have now discovered what underlies this failure. #immunotherapy #checkpointinhibitor #ovarian #cancer #biome #flagellin
https://www.instagram.com/reel/DHDygk-shuL/ -
Improving Ovarian Cancer Immunotherapy: Cancer immunologists at the University of Virginia have now discovered what underlies this failure. #immunotherapy #checkpointinhibitor #ovarian #cancer #biome #flagellin
https://www.instagram.com/reel/DHDygk-shuL/ -
This one is for adults with primary advanced or recurrent endometrial cancer.
"This new approval is based on data from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868. Results reported last year in the New England Journal of Medicineshowed a 70% lower risk of disease progression when patients were treated with pembrolizumab and chemotherapy."
#Immunology #Immunotherapy #CheckpointInhibitor
https://www.cancerresearch.org/blog/june-2024/keytruda-receives-40th-fda-approval?utm_source=Social&utm_medium=LinkedIn&utm_campaign=CRI&utm_id=CRI -
This one is for adults with primary advanced or recurrent endometrial cancer.
"This new approval is based on data from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868. Results reported last year in the New England Journal of Medicineshowed a 70% lower risk of disease progression when patients were treated with pembrolizumab and chemotherapy."
#Immunology #Immunotherapy #CheckpointInhibitor
https://www.cancerresearch.org/blog/june-2024/keytruda-receives-40th-fda-approval?utm_source=Social&utm_medium=LinkedIn&utm_campaign=CRI&utm_id=CRI -
This one is for adults with primary advanced or recurrent endometrial cancer.
"This new approval is based on data from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868. Results reported last year in the New England Journal of Medicineshowed a 70% lower risk of disease progression when patients were treated with pembrolizumab and chemotherapy."
#Immunology #Immunotherapy #CheckpointInhibitor
https://www.cancerresearch.org/blog/june-2024/keytruda-receives-40th-fda-approval?utm_source=Social&utm_medium=LinkedIn&utm_campaign=CRI&utm_id=CRI -
This one is for adults with primary advanced or recurrent endometrial cancer.
"This new approval is based on data from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868. Results reported last year in the New England Journal of Medicineshowed a 70% lower risk of disease progression when patients were treated with pembrolizumab and chemotherapy."
#Immunology #Immunotherapy #CheckpointInhibitor
https://www.cancerresearch.org/blog/june-2024/keytruda-receives-40th-fda-approval?utm_source=Social&utm_medium=LinkedIn&utm_campaign=CRI&utm_id=CRI -
"Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who’s who of leading drug developers have pumped money."
#Immunology #immunotherapy #CheckpointInhibitor -
"Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who’s who of leading drug developers have pumped money."
#Immunology #immunotherapy #CheckpointInhibitor -
"Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who’s who of leading drug developers have pumped money."
#Immunology #immunotherapy #CheckpointInhibitor -
"Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who’s who of leading drug developers have pumped money."
#Immunology #immunotherapy #CheckpointInhibitor -
AlphaFold & PDL1
"Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist."
#Immunology #CheckpointInhibitor -
AlphaFold & PDL1
"Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist."
#Immunology #CheckpointInhibitor -
AlphaFold & PDL1
"Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist."
#Immunology #CheckpointInhibitor -
AlphaFold & PDL1
"Here, we test a protein design pipeline that uses iterative rounds of deep learning (DL)-based structure prediction (AlphaFold2) and sequence optimization (ProteinMPNN) to design autoinhibitory domains (AiDs) for a PD-L1 antagonist."
#Immunology #CheckpointInhibitor -
The effects of the CTLA4 deletion were not very surprising, what's fascinating here is how it compares to the double mutants (PD1/CTLA4).
"CTLA4 disrupted CART19 cells display prolonged surface CAR expression, increased proliferation, and enhanced CART19 effector function supported by unopposed CD28 co-stimulation, which is lost in CART19 cells deficient for both PD-1 and CTLA4"
#Immunology #Immunotherapy #CheckpointInhibitor #CTLA4 #CARTcells
https://www.cell.com/immunity/fulltext/S1074-7613(23)00407-7#secsectitle0075
-
The effects of the CTLA4 deletion were not very surprising, what's fascinating here is how it compares to the double mutants (PD1/CTLA4).
"CTLA4 disrupted CART19 cells display prolonged surface CAR expression, increased proliferation, and enhanced CART19 effector function supported by unopposed CD28 co-stimulation, which is lost in CART19 cells deficient for both PD-1 and CTLA4"
#Immunology #Immunotherapy #CheckpointInhibitor #CTLA4 #CARTcells
https://www.cell.com/immunity/fulltext/S1074-7613(23)00407-7#secsectitle0075
-
The effects of the CTLA4 deletion were not very surprising, what's fascinating here is how it compares to the double mutants (PD1/CTLA4).
"CTLA4 disrupted CART19 cells display prolonged surface CAR expression, increased proliferation, and enhanced CART19 effector function supported by unopposed CD28 co-stimulation, which is lost in CART19 cells deficient for both PD-1 and CTLA4"
#Immunology #Immunotherapy #CheckpointInhibitor #CTLA4 #CARTcells
https://www.cell.com/immunity/fulltext/S1074-7613(23)00407-7#secsectitle0075
-
The effects of the CTLA4 deletion were not very surprising, what's fascinating here is how it compares to the double mutants (PD1/CTLA4).
"CTLA4 disrupted CART19 cells display prolonged surface CAR expression, increased proliferation, and enhanced CART19 effector function supported by unopposed CD28 co-stimulation, which is lost in CART19 cells deficient for both PD-1 and CTLA4"
#Immunology #Immunotherapy #CheckpointInhibitor #CTLA4 #CARTcells
https://www.cell.com/immunity/fulltext/S1074-7613(23)00407-7#secsectitle0075
-
A clinical trial assessing a synthetic antibody to generate an immediate response and also generate a more durable treatment for solid tumor cancers, advanced to a mid-stage study.
https://sciencebusiness.technewslit.com/?p=45068
#News #Press #Science #Business #Cancer #Biotechnology #ClinicalTrial #Immunotherapy #AdverseEffects #CheckpointInhibitor #Antibody #ImmuneSystem #TCells #InnateImmuneSystem
-
A clinical trial assessing a synthetic antibody to generate an immediate response and also generate a more durable treatment for solid tumor cancers, advanced to a mid-stage study.
https://sciencebusiness.technewslit.com/?p=45068
#News #Press #Science #Business #Cancer #Biotechnology #ClinicalTrial #Immunotherapy #AdverseEffects #CheckpointInhibitor #Antibody #ImmuneSystem #TCells #InnateImmuneSystem
-
A clinical trial assessing a synthetic antibody to generate an immediate response and also generate a more durable treatment for solid tumor cancers, advanced to a mid-stage study.
https://sciencebusiness.technewslit.com/?p=45068
#News #Press #Science #Business #Cancer #Biotechnology #ClinicalTrial #Immunotherapy #AdverseEffects #CheckpointInhibitor #Antibody #ImmuneSystem #TCells #InnateImmuneSystem
-
A clinical trial assessing a synthetic antibody to generate an immediate response and also generate a more durable treatment for solid tumor cancers, advanced to a mid-stage study.
https://sciencebusiness.technewslit.com/?p=45068
#News #Press #Science #Business #Cancer #Biotechnology #ClinicalTrial #Immunotherapy #AdverseEffects #CheckpointInhibitor #Antibody #ImmuneSystem #TCells #InnateImmuneSystem
-
Very interesting case report of pulse methylprednisolone in treatment of steroid-refractory #Immune #CheckPointInhibitor #pneumonitis
We also treated a patient with a grade IV pneumonitis with high dose steroid. My observation is a very rapid improvement, within 48h.
Further research is needed but it could be promising for life-threatening immune checkpoint inhibitor reaction
-
Very interesting case report of pulse methylprednisolone in treatment of steroid-refractory #Immune #CheckPointInhibitor #pneumonitis
We also treated a patient with a grade IV pneumonitis with high dose steroid. My observation is a very rapid improvement, within 48h.
Further research is needed but it could be promising for life-threatening immune checkpoint inhibitor reaction
-
Very interesting case report of pulse methylprednisolone in treatment of steroid-refractory #Immune #CheckPointInhibitor #pneumonitis
We also treated a patient with a grade IV pneumonitis with high dose steroid. My observation is a very rapid improvement, within 48h.
Further research is needed but it could be promising for life-threatening immune checkpoint inhibitor reaction
-
What if we could trace #cytotoxic #Tcells throughout the human body before and during #cancer #immunotherapy?
Researchers at the University of Groningen have used a CD8-specific positron emission tomography (#PET) tracer in a phase 1/2 clinical trial. Patients with solid tumors were imaged before and ~30 days after starting treatment with #antibodies against PD-L1, PD-1, and/or CTLA-4.
Article in Nature Medicine: https://www.nature.com/articles/s41591-022-02084-8
-
What if we could trace #cytotoxic #Tcells throughout the human body before and during #cancer #immunotherapy?
Researchers at the University of Groningen have used a CD8-specific positron emission tomography (#PET) tracer in a phase 1/2 clinical trial. Patients with solid tumors were imaged before and ~30 days after starting treatment with #antibodies against PD-L1, PD-1, and/or CTLA-4.
Article in Nature Medicine: https://www.nature.com/articles/s41591-022-02084-8
-
What if we could trace #cytotoxic #Tcells throughout the human body before and during #cancer #immunotherapy?
Researchers at the University of Groningen have used a CD8-specific positron emission tomography (#PET) tracer in a phase 1/2 clinical trial. Patients with solid tumors were imaged before and ~30 days after starting treatment with #antibodies against PD-L1, PD-1, and/or CTLA-4.
Article in Nature Medicine: https://www.nature.com/articles/s41591-022-02084-8
-
What if we could trace #cytotoxic #Tcells throughout the human body before and during #cancer #immunotherapy?
Researchers at the University of Groningen have used a CD8-specific positron emission tomography (#PET) tracer in a phase 1/2 clinical trial. Patients with solid tumors were imaged before and ~30 days after starting treatment with #antibodies against PD-L1, PD-1, and/or CTLA-4.
Article in Nature Medicine: https://www.nature.com/articles/s41591-022-02084-8
-
What if we could trace #cytotoxic #Tcells throughout the human body before and during #cancer #immunotherapy?
Researchers at the University of Groningen have used a CD8-specific positron emission tomography (#PET) tracer in a phase 1/2 clinical trial. Patients with solid tumors were imaged before and ~30 days after starting treatment with #antibodies against PD-L1, PD-1, and/or CTLA-4.
Article in Nature Medicine: https://www.nature.com/articles/s41591-022-02084-8
-
"Won et al. demonstrate that PD1
inhibitor treatment alone induces
myocarditis in A/J mice, creating a mouse model for immune-checkpoint-inhibitor-associated myocarditis." -
"Won et al. demonstrate that PD1
inhibitor treatment alone induces
myocarditis in A/J mice, creating a mouse model for immune-checkpoint-inhibitor-associated myocarditis."